Patents Examined by Jeffrey S. Parkin
  • Patent number: 8470526
    Abstract: The present invention provides novel methods for treating and preventing coronary artery disease in HIV-1-infected individuals by interfering with Nef-mediated effect on ABCA1. The invention further provides novel methods for suppressing HIV infection by stimulating cholesterol efflux from cells by stimulating expression of ABCA1 in HIV-1-infected individuals. These methods take advantage of the finding that Nef, a regulatory protein of HIV-1, (1) diminishes expression of ATP-binding cassette transporter A1 (ABCA1), the main transporter of cholesterol from cells to extracellular acceptors; and (2) impairs cholesterol efflux from HIV-1-infected macrophages leading to cholesterol accumulation and formation of foam cells, which is a characteristic feature of atherosclerosis.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: June 25, 2013
    Assignee: The George Washington University
    Inventors: Michael Bukrinsky, Dmitri Sviridov
  • Patent number: 8454972
    Abstract: The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: June 4, 2013
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, GenVec, Inc.
    Inventors: Gary J. Nabel, Ling Xu, Bimal Chakrabarti, Lan Wu, Zhi-yong Yang, Jason G. D. Gall, C. Richter King, Zengguang Wang
  • Patent number: 8367061
    Abstract: Novel anti-idiotype monoclonal antibodies are described which are capable of specifically reacting with the idiotype of human anti-gp120 antibodies, of inhibiting the binding between the gp120 antigen and human anti-gp120 antibodies, and of evoking a neutralising anti-gp120 immune response in an animal host to which they are administered. The anti-idiotype antibodies of the invention can be identified based on the amino acid sequences of the variable portions of their light and heavy chains. In addition, a method for obtaining a panel of anti-idiotype monoclonal antibodies, expression vectors and transformed host cells usable in a recombinant DNA procedure in order to generate the aforesaid anti-idiotype monoclonal antibodies, as well as the therapeutic, prophylactic and diagnostic use of such antibodies are disclosed.
    Type: Grant
    Filed: January 29, 2008
    Date of Patent: February 5, 2013
    Assignee: Pomona Ricera S.R.L.
    Inventors: Roberto Burioni, Massimo Clementi
  • Patent number: 8338089
    Abstract: The present invention relates, e.g., to a method for inhibiting infectivity of a lentivirus (e.g., a lentivirus which expresses a Viral infectivity factor (Vif) protein), such as, e.g., SIV, SHIV and/or HIV, comprising contacting a cell which is producing the virus with an antiviral-effective amount of a membrane-permeable Zinc (Zn) chelator, wherein the antiviral-effective amount of the Zn chelator does not substantially inhibit proteins in the cell which contain Zn-binding motifs other than lentivirus Vif. Kits and pharmaceutical compositions are also disclosed, as is a method for identifying inhibitors of lentiviruses that target a specific zinc-binding motif of the lentivirus Vif protein.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: December 25, 2012
    Assignee: The Johns Hopkins University
    Inventors: Xiao-Fang Yu, Elana S. Erhlich, Xiao Zuoxiang
  • Patent number: 8323661
    Abstract: The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: December 4, 2012
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder
  • Patent number: 8323662
    Abstract: Materials and methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein are provided. More specifically, methods for generating such materials include culturing in a culture medium including kifunensine a virus packaging cell with a lentiviral vector genome including a polynucleotide encoding an exogenous antigen, a polynucleotide encoding a Sindbis E2 glycoprotein that preferentially binds dendritic cells expressing DC-SIGN, and a polynucleotide encoding a Vpx protein or a Vpr protein that retains SAMHD1-inhibiting activity, followed by isolating a pseudotyped lentiviral vector particle that preferentially binds dendritic cells expressing DC-SIGN.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: December 4, 2012
    Assignee: Immune Design Corp.
    Inventors: Christopher James Nicolai, Semih Ullah Tareen
  • Patent number: 8318419
    Abstract: The present invention provides for testing methods to determine an effective testing agent that affects the activity of the HIV Gag protein at the plasma membrane of a cell, and specifically, effecting changes in the structural conformation of at least one fatty acid of PI(4,5)P2, a member of a family of differentially phosphorylated phosphatidylinositides, wherein inhibition of the extension of such fatty acid into the MA domain of the Gag protein reduces binding of Gag to the plasma membrane, thereby inhibiting virus particle assembly and subsequent replication of the HIV virus.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: November 27, 2012
    Assignee: University of Maryland, Baltimore County
    Inventors: Michael F. Summers, Jamil S. Saad
  • Patent number: 8309098
    Abstract: The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: November 13, 2012
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder
  • Patent number: 8293465
    Abstract: The present invention relates to an antibody mimetic of carbohydrate binding module (CBM) which specifically binds to an epitope on HIV glycoprotein. The present invention also relates to a method of detecting HIV glycoprotein.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: October 23, 2012
    Assignee: National Tsing Hua University
    Inventors: Margaret Dah-Tsyr Chang, Yuan-Chuan Lee, Rong-Yuan Huang, Shu-Chuan Lin, Wei-I Chou, Shi-Hwei Liu
  • Patent number: 8287881
    Abstract: The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.
    Type: Grant
    Filed: May 29, 2007
    Date of Patent: October 16, 2012
    Assignee: GENEART AG
    Inventors: Ralf Wagner, Markus Graf, Ludwig Deml, Kurt Bieler
  • Patent number: 8282926
    Abstract: The present invention relates, e.g., to an isolated peptide comprising a sequence of contiguous amino acids that is at least about 60% identical (e.g., at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 100% identical) to the sequence E-W-Q-K-E-G-L-V-T-L-W-L (SEQ ID NO:1), or an active variant of an isolated peptide comprising SEQ ID NO:1. Neutralizing antibodies generated by, or specific for, such peptides are also described, in particular antibodies which are specific for the HIV co-receptor, CCR5, and which inhibit infection of a host cell by HIV. Neutralizing single strand and complete human monoclonal antibodies against CCR5 are described. Methods of using such peptides or antibodies, for inhibiting infection by HIV, are also described.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: October 9, 2012
    Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Hana Golding, Surender Khurana
  • Patent number: 8282937
    Abstract: The cold-adapted master strain A/Ann Arbor/6/60 7PI (H2N2) and progenitor wild type E2(3) viral strains have been deposited and their genomic sequences identified. Seven nucleotide differences were found between the sequences identified herein and the previously published sequences for cold-adapted A/Ann Arbor/6/60 genes. The cold-adapted live influenza virus of the present invention can be reasserted with a variety of epidemic wild type influenza viruses and used to produce vaccines to prophylactically and therapeutically treat influenza.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: October 9, 2012
    Assignee: The Regents of the University of Michigan
    Inventors: Hunein Maassab, Martha Louise Herlocher
  • Patent number: 8282938
    Abstract: The present invention provides an avian influenza vaccine containing a peptide-bound liposome wherein; the peptide contains: (1) an amino acid sequence shown by any one of SEQ ID NO:1 to 9, or (2) an amino acid sequence shown by any one of SEQ ID NO:1 to 9 wherein one or two amino acids are substituted, has a length of 9 to 11 amino acids, and is capable of inducing HLA-restricted cytotoxic T lymphocytes; wherein the liposome contains a phospholipid having an acyl group with 14 to 24 carbon atoms and one unsaturated bond or a hydrocarbon group with 14 to 24 carbon atoms and one unsaturated bond, and a liposome stabilizer; and wherein the peptide is bound to the surface of the liposome.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: October 9, 2012
    Assignees: National Institute of Infectious Diseases, National University Corporation Hokkaido University, Saitama Medical University, NOF Corporation
    Inventors: Tetsuya Uchida, Maiko Taneichi, Kiichi Kajino, Masanori Matsui, Hiroshi Oda
  • Patent number: 8232379
    Abstract: The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: July 31, 2012
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventor: Gwong-Jen J. Chang
  • Patent number: 8226955
    Abstract: Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Method of diagnosis, treatment and prevention using the polypeptides are also provided.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: July 24, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Susan W Barnett, Indresh K Srivastava
  • Patent number: 8227586
    Abstract: Provided herein is a novel human polyomavirus, its nucleic acid sequence, as well as methods to detect and diagnosis the presence of the polyomavirus.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: July 24, 2012
    Assignees: Washington University, Queensland Health
    Inventors: David Wang, Guang Wu, Anne Gaynor, Michael Nissen, Theo Sloots
  • Patent number: 8221768
    Abstract: The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus or of a chimeric immunogenic flavivirus antigen comprising sequence from more than one flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: July 17, 2012
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventor: Gwong-Jen J. Chang
  • Patent number: 8206720
    Abstract: Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.
    Type: Grant
    Filed: June 8, 2005
    Date of Patent: June 26, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Vega Masignani, Maria Scarselli, Barbara Capecchi, Victoria Sharma, Susan W. Barnett, Indresh K. Srivastava, Rino Rappuoli
  • Patent number: 8202688
    Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.
    Type: Grant
    Filed: November 20, 2002
    Date of Patent: June 19, 2012
    Assignees: University of Iowa Research Foundation, Coley Pharmaceutical GmbH, Ottawa Health Research Institute
    Inventors: Heather L. Davis, Joachim Schorr, Arthur M. Krieg
  • Patent number: RE43823
    Abstract: Compositions are provided that comprise antibody against coreceptors for human immunodeficiency virus such as CCR5 and CXCR4. In particular, monoclonal human antibodies against human CCR5 are provided that bind to CCR5 with high affinity and are capable of inhibiting HIV infection at low concentrations. The antibodies can be used as prophylactics or therapeutics to prevent and treat HIV infection, for screening drugs, and for diagnosing diseases or conditions associated with interactions with HIV coreceptors.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: November 20, 2012
    Assignee: Genetastix Corporation
    Inventors: Shaobing Hua, Michelle Haynes Pauling, Li Zhu